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Abstract
Background: Adult hippocampal neurogenesis has been implicated in the mechanism of antidepressant action, and
neurotrophic factors can mediate the neurogenic changes underlying these effects. The neurotrophic factor neuregulin-1
(NRG1) is involved in many aspects of brain development, from cell fate determination to neuronal maturation. However,
nothing is known about the influence of NRG1 on neurodevelopmental processes occurring in the mature hippocampus.
Methods: Adult male mice were given subcutaneous NRG1 or saline to assess dentate gyrus proliferation and neurogenesis,
as well as cell fate determination. Mice also underwent behavioral testing. Expression of ErbB3 and ErbB4 NRG1 receptors in
newborn dentate gyrus cells was assessed at various time points between birth and maturity. The phenotype of ErbB-
expressing progenitor cells was also characterized with cell type-specific markers.
Results: The current study shows that subchronic peripheral NRG1b administration selectively increased cell proliferation
(by 71%) and neurogenesis (by 50%) in the caudal dentate gyrus within the ventral hippocampus. This pro-proliferative
effect did not alter neuronal fate, and may have been mediated by ErbB3 receptors, which were expressed by newborn
dentate gyrus cells from cell division to maturity and colocalized with SOX2 in the subgranular zone. Furthermore, four
weeks after cessation of subchronic treatment, animals displayed robust antidepressant-like behavior in the absence of
changes in locomotor activity, whereas acute treatment did not produce antidepressant effects.
Conclusions: These results show that neuregulin-1b has pro-proliferative, neurogenic and antidepressant properties, further
highlight the importance of peripheral neurotrophic factors in neurogenesis and mood, and support the role of
hippocampal neurogenesis in mediating antidepressant effects.
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Introduction
Adult hippocampal neurogenesis, the evolutionarily conserved
process by which new granule cell neurons are added to the
dentate gyrus (DG) of the hippocampus, has been implicated in
several brain functions, including affective modulation. According
to the neurogenic theory of antidepressant effects, increasing
hippocampal neurogenesis can ameliorate depressive symptoms
([1–8]; see [9–11] for review), although it is controversial whether
deficits in neurogenesis are sufficient to cause a depressive
phenotype [5,12–16]. In support of the involvement of neurogen-
esis in antidepressant effects, antidepressant treatments increase
hippocampal neurogenesis [1,17], ablating hippocampal neuro-
genesis can prevent antidepressant effects ([3,5,12,18]; although
see [13,19]), and the latency of these effects in humans and
animals correlates with the time required for newborn DG
neurons to integrate into mature circuits [6].
Neurotrophic factors have been proposed to mediate the
neurogenic response to antidepressants, with strong evidence that
peripherally circulating neurotrophic factors can modulate both
mood and neurogenesis [20–25]. In particular, chronic peripheral
administration of brain-derived neurotrophic factor (BDNF) has
been reported to increase neurogenesis [25] and to induce
antidepressant and anxiolytic effects [25,26]. Interestingly, serum
levels of BDNF are also reduced in depressed patients and increased
by antidepressant treatment [23,27], raising the possibility that
peripheral activity of this neurotrophic factor could affect mood by
modulating central neurophysiological processes such as adult
hippocampal neurogenesis. Further support for a peripheral
influence of neurotrophins on mood arises from the demonstration
that peripheral administration of the pro-neurogenic hormone
insulin-like growth factor-I, which can cross the blood-brain barrier
(BBB), produces antidepressant-like behavior [21].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26610The neuregulin (NRG) family of epidermal growth factor-
related proteins comprises a wide variety of soluble and
membrane-bound proteins that mediate their effects through
ErbB2-ErbB4 tyrosine kinase receptors [28,29]. The diversity of
NRG proteins, arising mainly from alternative splicing, is
particularly well-documented for the neurotrophic factor NRG1,
which includes at least fifteen isoforms. In addition to being
expressed in the brain, some NRG1 isoforms are also widely
expressed in the periphery [30–32]. In particular, NRG1b, the
most widespread NRG1 isoform in the brain, is found in the
circulation, from which it can readily cross the adult BBB via
carrier-mediated transport and affect brain activity [33–36].
Studies of NRG1 signaling in the brain indicate prominent roles
for this protein during development, such as cell fate determina-
tion [37], axon guidance [38], radial glia elongation [39–41],
neuronal migration [42,43] and dendritic growth [44].
Despite our rapidly expanding knowledge of NRG1 functions in
the developing brain, very little is currently known about the
influence of this neurotrophic factor on neurodevelopmental
processes occurring at maturity. NRG1 administration in the
adult subventricular zone (SVZ), the main proliferative region in
the adult brain, has been shown to affect progenitor organization
and migration [45]. However, a possible role for NRG1 signaling
in modulating hippocampal neurogenesis remains to be examined
[46]. Here, we exploited the fact that NRG1b readily crosses the
BBB to study the consequences of subchronic peripheral
administration of this neurotrophic factor on hippocampal
neurogenesis. Based on previous studies showing that NRG1 is
pro-proliferative in vitro[47,48] and that neurotrophic factors
increase proliferation and neurogenesis in the adult hippocampus
[20,22,25], we hypothesized that NRG1b treatment would
stimulate DG proliferation, leading to an increase in hippocampal
neurogenesis. We further hypothesized that this increase in
neurogenesis would lead to antidepressant effects, in line with
studies demonstrating an association between these phenomena
[3,5,12,18], as well as those showing antidepressant effects after
neurotrophic factor administration [21,25]. We show that this
treatment strongly stimulates DG cell proliferation exclusively in
the ventral hippocampus, leading to an increase in neurogenesis
that is accompanied by robust antidepressant-like behavior.
Materials and Methods
Animals
Adult male C57BL/6 mice were purchased from Charles River
Canada. For ErbB3/SOX2/nestin triple labeling, group-housed
transgenic mice expressing GFP at the nestin promoter (nestin-
GFP; [49]) on a C57BL/6 background were used. All animals
were 2 months of age and housed in groups (except animals for
neurogenesis and behavioral experiments, which were isolated) on
Figure 1. Experimental timelines. LM, locomotor task; FST, forced swim test.
doi:10.1371/journal.pone.0026610.g001
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experiments followed the policies and guidelines of the Canadian
Council on Animal Care and were approved by McGill
University’s Animal Care Committee (approval ID: 5473).
NRG1b and BrdU administration
After anesthesia with isoflurane, mice were implanted with
subcutaneous osmotic mini-pumps (Alzet) containing either
recombinant NRG1b type-I (EGF domain dissolved in sterile
0.9% saline, administered at a constant rate of 10 mg/d; R&D
Systems; accession # NP_039250) or vehicle (randomized groups
assignment). Animals were given a subcutaneous saline injection
and placed on a heating pad to recover, and were monitored post-
operatively for complications. An anti-inflammatory Carprofen
tablet was placed in each cage. Depleted mini-pumps were
removed from anesthetized animals after the administration
period, and pump depletion was verified.
To evaluate proliferation, mice (n=6/group) were sacrificed at
the end of a 24 h NRG1b or vehicle administration period, having
received two injections of bromodeoxyuridine (BrdU; Sigma;
50 mg/kg, i.p.) dissolved in sterile 0.9% saline with 0.4 M NaOH:
one immediately after mini-pump implantation, and the other two
hours prior to sacrifice. To evaluate neurogenesis (encompassing
proliferation, differentiation and survival), mice (n=7/group)
received BrdU twice daily during the 72 h NRG1b or vehicle
administration period and sacrificed 30 d after mini-pump
implantation. For immunohistochemical (IHC) receptor colocali-
zation experiments, naive animals received BrdU 2 h, 24 h, 7 d, or
28 d prior to sacrifice (n=2/survival period), with the latter two
groups receiving two BrdU injections on the day of administration.
To determine the acute behavioral effects of NRG1b, mice were
given three 0.1 ml i.p. injections of NRG1b (3.33 mg; n=7) or
vehicle (n=8), 24 h, 12 h and 1 h prior to testing, and then
sacrificed (see Fig. 1 for experimental timelines).
Tissue processing
Animals were deeply anesthetized with a cocktail of ketamine,
xylazine and acepromazine (0.1 ml/100 g), and perfused through
the heart with ice-cold phosphate-buffered saline (PBS) followed
by 4% formaldehyde in 0.1 M phosphate buffer. Brains were then
rapidly removed, postfixed at 4uC for 24 h in fixative, then
transferred to a 30% sucrose solution until equilibrium was
reached. Brains were cut using a cryostat into serial 40 mm-thick
coronal sections, which were placed in a cryoprotectant solution
(glycerol:ethylene glycol:PBS, 3:3:4) and stored at 220uC.
BrdU immunohistochemistry
Unless otherwise specified, all IHC incubations were at room
temperature. The section-sampling fraction was 1/8. Omitting
primary antibodies resulted in an absence of specific staining for all
IHC protocols. Rinses with PBS preceded all steps except the
addition of primary antibodies and addition of H2O2. For BrdU
light microscopy IHC, sections were pre-treated for 1.5 h in PBS
containing 0.2% Triton X-100 (PBS-T; Fisher), 10 min in PBS
containing 0.9% H2O2, and 30 min at 37uC in PBS with 2N HCl
to denature DNA. Sections were then incubated in PBS-T
containing 2% Normal Goat Serum (NGS) for 30 min, and then
overnight at 4uC in the same solution with monoclonal rat anti-
BrdU (1:1000; Serotec). Sections were then incubated for 1 h in
biotinylated goat anti-rat antibody (1:200; Vector Laboratories),
followed for 30 min by the avidin-biotin complex procedure (ABC
Kit, Vectastain Elite, Vector). Labeling was revealed with a
Figure 2. Proliferative and neurogenic effects of peripheral
NRG1 administration. (A) NRG1 increases DG cell proliferation, in the
caudal (71%; p=0.0011), but not rostral (p=0.20), DG. (B) NRG1
increased the number of BrdU-IR cells 28 d after administration. As with
proliferation, this increase is significant in the caudal (50%; p=0.013),
but not rostral (p=0.29), DG. Bars represent mean 6 SEM. *p,0.05;
**p,0.025; ***p,0.005. CAU, caudal; NRG, neuregulin; ROS, rostral; SAL,
saline; TOT, total.
doi:10.1371/journal.pone.0026610.g002
Figure 3. SVZ cell proliferation. NRG1 administration does not
affect SVZ proliferation (p=0.34). Bars represent mean 6 SEM. NRG,
neuregulin; SAL, saline.
doi:10.1371/journal.pone.0026610.g003
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slides, dehydrated, and coverslipped with Permount (Fisher
Scientific).
BrdU/NeuN double-labeling
To determine the proportions of newborn cells that became
neurons, coronal brain sections from the neurogenesis experiment
were incubated overnight at 4uC with rat anti-BrdU (as above) and
mouse anti-NeuN (1:200; Chemicon) antibodies in 2% NGS in
PBS-T, after consecutive incubations in PBS-T (2 h), 2N HCl in
PBS at 37uC (30 min) and PBS-T containing 2% NGS (1 h). This
was followed by a 1.5 h incubation in fluorescent DyLight 594-
labeled goat anti-rat (1:1500; Jackson) and DyLight 488-labeled
goat anti-mouse (1:500; Jackson) antibodies in 2% NGS in PBS-T.
Sections were mounted on glass slides and coverslipped with
ProLong Gold antifade reagent with DAPI (Invitrogen).
BrdU/ErbB double-labeling
Sections from animals injected with BrdU 2 h, 24 h, 7 d, or 28
d prior to sacrifice were incubated for 2 h in PBS-T. Sections
were then incubated for 30 min in PBS at 37uCi n1 NH C lt o
denature DNA, and incubated in 2% NGS in PBS-T for 2 h
before an overnight incubation at 4uC in rat anti-BrdU (as
above) and monoclonal mouse anti-ErbB4 (Thermo Scientific;
1:100) or monoclonal rabbit anti-ErbB3 (accession # Q61526,
Santa Cruz; 1:100) in the same solution. Sections were then
incubated for 1.5 h in DyLight 594 goat anti-rat (1:1500) and
DyLight 488 goat anti-rabbit (1:500) or goat anti-mouse (1:100
or 1:200) antibodies (Jackson) in PBS-T containing 2% NGS.
Sections were mounted on slides and coverslipped and coded as
above.
The anti-ErbB4 antibody is directed against an extracellular
domain of the ErbB4 receptor [50], and the anti-ErbB3 antibody
is directed against the C-terminal domain [51]. The specificity of
the latter antibody has been validated previously in ErbB3-
knockout tissues [52,53]. In addition, we confirmed the staining
pattern using a different anti-ErbB3 antibody raised in mice
(Millipore, 1:25, 1:50 and 1:100; accession # P21860; not shown)
under light microscopy conditions with DAB. Furthermore,
immunofluorescence double-labeling with both anti-ErbB3 anti-
bodies revealed colocalization throughout the DG (wide-field and
confocal microscopy).
ErbB3/SOX2/nestin triple-labeling
Nestin-GFP mouse brain sections were incubated for 2 h in
PBS-T and 1 h in 2% NGS in PBS-T, then overnight at 4uCi n
rabbit anti-ErbB3 (as above) and mouse anti-SOX2 (R&D 1:200;
accession # P48431). The staining pattern of the latter (which has
been validated previously in SOX2-knockout tissue [54]) was
confirmed with an additional anti-SOX2 antibody (Millipore; 1:12
000 and 1:20 000; accession # P48431; not shown) under light
microscopy conditions with DAB. Secondary antibodies (DyLight
594 goat anti-rabbit and Dylight 649 goat anti-mouse, 1:500,
Jackson) were added for 1.5 h. Sections were mounted on slides
and coverslipped as above. As a negative control, a nestin-GFP-
negative sibling did not show GFP staining using wide-field and
confocal microscopy.
Cell quantification
All quantifications and analyses were done by an investigator
blind to experimental groups. BrdU-immunoreactive (-IR) cells in
the DG of the hippocampus were counted using a Leica CME
with a 40X 0.65NA E2 achromat objective (proliferation) or a
Leica DM 2500 with a 40X 0.75 NA HCX PL Fluotar objective
(neurogenesis). Cell counts were expressed as average numbers per
DG. Proliferation of cells in the SVZ was determined at 40X (0.75
NA UPlan FL N objective) on an Olympus BX51 microscope
equipped with a motorized stage and CX-9000 camera (MBF),
using an optical fractionator (OF) probe (Stereo Investigator,
MBF). A pilot study conducted to establish sampling parameters
revealed a Gunderson coefficient of error (CE) (m=1) ,0.05. The
size of the counting frame for cell estimation was 500 mm
2,
dissector height was set to 14 mm, and guard zone distance to
1 mm. The average sampling area was 6072.5 mm
2. As the OF
procedure provided cell count estimates and not absolute cell
numbers, density of BrdU-IR cells was determined as the
estimated population using section thickness divided by the
Cavalieri volume corrected for overprojection. Gunderson CEs
(m=1) for all animals were ,0.05.
Figure 4. Neuronal differentiation. NRG1 administration does not affect the proportion of BrdU-IR cells that differentiated into NeuN-IR neurons,
either overall (p=0.91) or in the rostral (p=1.0) or caudal (p=0.90) subregions. Bars represent mean 6 SEM. NRG, neuregulin; SAL, saline.
doi:10.1371/journal.pone.0026610.g004
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To rule out group differences in surface area or volume (as
calculated by planimetry and Cavalieri estimation), the SVZs and
DGs of each brain used in cell quantification were traced on the
Olympus BX51 microscope mentioned above with a 10X UPlan
FL N 0.3 NA objective using the Stereo Investigator software
package (MBF). SVZs and DGs as well as rostral (21.46 to
22.54 mm from bregma [55]) and caudal (22.55 to 23.80 mm
from bregma) DG subregions presented no significant difference
between groups for any of the measures of this analysis, including
total and average surface area and total and average volume, both
corrected and uncorrected for overprojection (ps.0.05).
Confocal microscopy
Multiple-labeling analyses were conducted at 40X (1.3 NA
Plan-Neofluar 40x Oil DIC objective) on a Zeiss LSM510 Meta
confocal microscope equipped with an Axiovert 200 M stand and
motorized stage (Carl Zeiss Canada), using 405 nm, 488 nm,
543 nm, and 633 nm wavelength lasers. Images were obtained
using the Zeiss Aim software package (Carl Zeiss Canada), at a
pixel size of 0.11 mm for x and y, a scan average of $4 frames, a
pixel dwell time of $3.20 ms, and optical slice of ,3 mm sampled
at an interval of ,1.5 mm. Images were unaltered except for
overall brightness and contrast. For quantitative colocalization
analyses, 20 random cells from the rostral and caudal DG (10/
subregion from multiple DGs) of each animal were analyzed, and
data expressed as the percentage of BrdU-IR cells that were also
NeuN-IR or ErbB-IR.
Behavior
Animals in the neurogenesis experiment were assessed in a
locomotor task and in the forced swim test (FST) 28 d and 29 d,
respectively, after the onset of the 72 h NRG1b or saline
administration period, or 40 min and 1 h after the final injection
in the acute behavior experiment. The forced swim test (FST) was
chosen for its implication as a hippocampal neurogenesis-
dependent task ([12,18]; although see [13,19]), and the locomotor
task served to determine whether putative antidepressant effects
were due to changes in general locomotor activity. To study
locomotor behavior, mice were placed individually into acrylic
Versamax RS2USB v4.00 Animal Activity Monitor boxes (.2 m
L6.2 m W6.3 m H; Accuscan) in a room lit by red light for a
period of 90 min (20 min for the acute behavior experiment).
Locomotor behavior was analyzed automatically by the Versamax
VMX 1.4B software system (AccuScan). Three periods of activity
were analyzed: no habituation (first 10 min activity), 10 min of
habituation (second 10 min activity) and extended habituation for
the neurogenesis experiment (30 min habituation, 60 min activ-
ity). For the FST, mice were placed in 4 L glass beakers (25 cm
depth, 15 cm diameter) 1/3
rd filled with water (25uC) for a period
of 10 minutes in a dimly lit room. Behavior was recorded by video
equipment and subsequently analyzed using Videotrack behav-
ioral tracking software (Viewpoint). The first two minutes were
treated as habituation, and the following four minutes analyzed for
duration of swimming and immobility behavior.
Figure 5. BrdU/ErbB3 colocalization. BrdU-IR cells (red) express
ErbB3 (green), at 2 h (Figs. S1 and S2)a n d2 4 h( above),
corresponding to the period in which cell proliferation is increased
following NRG1 administration, as well as 7 d and 28 d after birth (Fig.
S1 and S2). Scale bar=20 mm.
doi:10.1371/journal.pone.0026610.g005
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Normality of data was assessed using Shapiro-Wilk tests.
Parametric pair-wise comparisons were made using Student’s t-
tests. Non-parametric pair-wise comparisons were made with
Mann-Whitney U-tests. Comparisons within testing period time
points across the duration of the FST were made with Bonferroni-
corrected t- and U-tests. Values of p ,0.05 were considered to be
statistically significant.
Results
Proliferation
Mice were administered NRG1b or saline for 24 h (to evaluate
proliferation immediately after) or 72 h (to evaluate neurogenesis
and behavior four weeks later), and received injections of BrdU
during administration (see Fig. 1). After 24 h of NRG1
administration, cell proliferation in the DG, as assessed by
numbers of BrdU–IR cells, increased by 38% compared to
controls (p=0.013). Subregional analyses revealed that this
increase was highly significant in the caudal DG (71%;
p=0.0011), but non-significant in the rostral DG (p=0.29)
(Fig. 2A). Proliferation in the SVZ did not differ between groups
(p=0.34; Fig. 3).
Neurogenesis
Overall, BrdU-IR cell numbers in the DG increased four weeks
after NRG1b administration (31%; p=0.042). As with prolifera-
tion however, this increase was only significant in the caudal DG
(50%, p=0.013; rostral: p=0.20) (Fig. 2B). The proportion of
cells that differentiated into neurons in these animals did not vary
with treatment (overall: p=0.91; rostral DG: p=1.00 or caudal
DG: p=0.90; Fig. 4), indicating that the NRG1b-induced
increase in proliferation within the caudal DG led to increased
neurogenesis in this region.
BrdU-ErbB colocalization
To examine if these effects may have resulted from direct
stimulation of NRG1 receptors expressed by progenitor cells, we
determined at different post-BrdU injection time points whether
BrdU-IR in the DG colocalized with ErbB3- or ErbB4-IR (see
Fig. 1), as presence of one of these receptors is required for
NRG1-ErbB signaling. IR for both receptors were observed in the
DG in expression patterns similar to previous studies using these
and other antibodies [50,51,56]. In naive animals 7068% (rostral:
55616%; caudal: 8563%; mean %6SEM) of newborn cells were
found to express ErbB3 during the proliferative period (2 h and
24 h following BrdU injection; Figs. 5, S1 and S2). Interestingly,
colocalization was also observed 7 d and 28 d post-injection (Fig.
S1 and S2), suggesting a life-long influence for NRGs on the
activity of adult-born granule cells. BrdU-IR and ErbB4-IR were
never found to be colocalized in the DG.
ErbB3/nestin/SOX2 colocalization
To examine which neurogenic cell subtypes in the DG
expressed ErbB3, we analyzed the colocalization of ErbB3, nestin
and SOX2 in nestin-GFP animals (Fig 6). Colocalization was
predominately limited to the subgranular zone. Although both
SOX2 and nestin colocalized with ErbB3 in the rostral and caudal
DG, nestin and ErbB3 were only co-expressed in cells expressing
SOX2 (i.e. triple-labeled cells; Figs. 6A and S3A) and not in the
absence of SOX2, whereas ErbB3 and SOX2 also colocalized in
the absence of nestin (Fig. 6B and S3B), suggesting that the
neuronal precursor cells involved in the NRG1-induced prolifer-
ative increase express SOX2.
Behavior
The effects of subchronic (72 h) NRG1b treatment on
antidepressant-like behavior were assessed in the same animals
in which neurogenesis was examined. For all analyses of the
locomotor task, experimental groups did not differ in either
Figure 6. ErbB3/nestin/SOX2 colocalization. ErbB3-IR cells (red)i n
the DG colocalize with nestin (green) and SOX2 (blue) (arrow in A; Fig.
S3A), or with SOX2 in the absence of nestin (arrow in B; Fig. S3B), but
not nestin in the absence of SOX2. Arrowhead in B denotes a nestin-IR
cell that is negative for both ErbB3 and SOX2. Scale bar=20 mm.
doi:10.1371/journal.pone.0026610.g006
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st 10 min: p=0.30; 2
nd 10 min:
p=0.28; 60 min after 30 min habituation: p=0.26) or activity
duration (1
st 10 min: p=0.25; 2
nd 10 min: p=0.23; 60 min
after 30 min habituation: p=0.29) (Fig. 7). Treatment groups
did not differ in locomotor activity after acute treatment (24 h),
either initially (distance: p=0.67; duration: p=0.96) or after
10 min of habituation (distance: p=0.60; duration: p=0.67)
(Fig. 8).
NRG1b-treated animals showed decreased immobility (44%;
p=0.0062) and increased swimming (194%; p=0.0062) in the
FST four weeks after the administration period, suggesting that
NRG1b treatment had antidepressant effects. Bonferroni-correct-
ed temporal analyses revealed that these animals had significantly
increased swimming and decreased immobility throughout the
testing period (0.019#ps#0.039) except the fifth minute
(ps=0.11) (Fig. 9). Acute treatment with NRG1b did not produce
antidepressant effects in the FST compared to vehicle-treated
animals (immobility: p=0.15; swimming, p=0.15). During the
testing period treatment groups did not differ at any point
(0.37#ps#1.0) (Fig. 10).
Figure 7. Locomotor activity does not change in response to NRG1 administration. NRG1 administration does not affect locomotor activity
28 d after subchronic administration, either in distance (A, C, E) or duration (B, D, F). A, B: First 10 min of activity (distance: p=0.30; duration:
p=0.25). C, D: 10 min of activity after 10 min habituation (distance: p=0.28; duration: p=0.23). E, F: 60 min of activity after 30 min habituation
(distance: p=0.26; duration: p=0.29). Bars represent mean 6 SEM. NRG, neuregulin; SAL, saline.
doi:10.1371/journal.pone.0026610.g007
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This study shows that peripheral NRG1b administration
increases cell proliferation in the caudal (but not rostral) DG
within 24 h, and that this treatment leads to a similar increase in
local neurogenesis. This pro-proliferative effect did not influence
cell fate, and was likely mediated by ErbB3 receptors in SOX2-
expressing neuronal precursor cells. Given the magnitude of this
effect within such a relatively short period, it is likely that the
progenitor cells involved in this increase are the rapidly
proliferating type-II cells as opposed to the more quiescent type-
I stem cells [57], although the widespread expression of ErbB3 in
the DG leaves open the possibility of mature granule cells
contributing to this phenomenon. In addition, the large increase in
DG cell numbers was accompanied by antidepressant-like
behaviors four weeks after cessation of subchronic treatment, but
not acutely. NRG1b administration did not increase proliferation
in the SVZ, in agreement with previous findings [45], suggesting
that the pro-proliferative influence of NRG1b in neurogenic
regions of the adult brain in vivo is restricted to the caudal DG.
This region is localized within the ventral hippocampus
[17,58,59], which is structurally and functionally distinct from
the dorsal hippocampus [59–61]. Adult ventral hippocampal
lesions are anxiolytic and disrupt fear conditioning and memory
[60–64], whereas neonatal ventral hippocampus lesions are a well-
characterized model of schizophrenia [65,66]. In addition to its
role in anxiety, the ventral hippocampus and ventral hippocampal
neurogenesis have been implicated in depression, antidepressant-
related behavior and response to stress [4,9,12,17,67–72]. The
involvement of the ventral hippocampus in emotional modulation
may be linked to its connectivity, which includes projections to the
prefrontal cortex, amygdala, nucleus accumbens, olfactory bulb,
and hypothalamic-pituitary-adrenal axis-related structures
[60,61,73–75], and to its increased serotonergic innervation in
comparison with the dorsal hippocampus [9,76–78]. Interestingly,
NRG1 hypomorphic mice display disrupted ventral hippocampal–
nucleus accumbens transmission [79].
Treatments that induce neurogenic, antidepressant and anxio-
lytic effects typically do so after chronic - but not subchronic -
duration [2,3,17,18,80,81]. The present study demonstrates that
NRG1 has neurogenic and antidepressant effects with subchronic
(72 h) treatment. These effects were measured 28 d after cessation
of treatment (and long after exogenous NRG1b would have
degraded), a delay that mirrors the maturation period of neurons
born during treatment [82]. Given that these newborn neurons are
then in a state of increased plasticity [82], our results suggest that
boosting the number of highly plastic neurons in the ventral
hippocampus can mediate antidepressant effects. Notably, 24 h of
treatment was sufficient to increase ventral hippocampal cell
proliferation but not to produce antidepressant effects, supporting
the hypothesis that the latter are due to the hyperplastic state of
immature neurons and not simply an increased number of DG
Figure 8. Acute locomotor activity does not change in response to NRG1 administration. NRG1 administration does not affect locomotor
activity acutely after administration, either in distance (A, C) or duration (B, D). A, B: First 10 min of activity (distance: p=0.67; duration: p=0.96). C,
D: 10 min of activity after 10 min habituation (distance: p=0.60; duration: p=0.67). Bars represent mean 6 SEM. NRG, neuregulin; SAL, saline.
doi:10.1371/journal.pone.0026610.g008
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be neurogenesis-independent [19], in opposition to previous
studies [12,18]. However, our temporal paradigm shows that the
antidepressant effects seen here are concomitant with an increase
in adult-born granule cells. Although the current data indicate that
the antidepressant effects of NRG1 in particular may be
neurogenesis-dependent, they also offer support to the hypothesis
that established antidepressants such as SSRIs have a delayed
onset of clinical effectiveness (and require chronic treatment) due
to the delay required for treatment-induced newborn neurons to
mature and integrate into DG circuitry.
NRG1 has attracted widespread interest for its involvement in
the etiology of psychiatric conditions. Single nucleotide polymor-
phisms of the NRG1 gene have been associated with schizophrenia
and bipolar disorder [83–91]. Mice hypomorphic for NRG1 or
ErbB4 show behavioral abnormalities consistent with existing
animal models for schizophrenia, including abnormal prepulse
inhibition and enhanced response to cannabinoid and dopami-
nergic agonists [92–94]. Studies of clinical populations have
revealed decreased peripheral expression of NRG1b in schizo-
phrenic patients that increased with antipsychotic treatment
[30,31], which is particularly interesting as NRG1b can cross
the adult BBB and affect brain activity and behavior [33–36].
Schizophrenia has been associated with both abnormal NRG1
type-I signaling in the prefrontal cortex [95–97] and decreased
hippocampal neurogenesis [98,99]. In particular, some studies
suggest that NRG1 levels are decreased in the brains of depressed
and schizophrenic patients [95,96]. Decreased NRG1 activity may
negatively affect hippocampal neurogenesis in schizophrenic
patients, contributing to the etiology of this disorder. NRG1
administration could both reverse decreases in hippocampal
neurogenesis and ameliorate psychiatric symptoms. The potential
utility of NRG1b as a therapeutic that could be delivered
peripherally is supported by a recent Phase II clinical study
examining NRG1b as a treatment for chronic heart conditions,
which revealed that peripheral NRG1b administration does not
lead to serious adverse effects in humans [100].
In conclusion, this study is the first to suggest that NRG1b,a
peripherally and centrally expressed neurotrophic factor that
crosses the BBB, increases ventral hippocampal neurogenesis and
modulates mood as a putative antidepressant. It is also the first to
show that newborn DG cells express ErbB3 from birth to maturity.
That the behavioral effects were not observed acutely but were
present four weeks after subchronic treatment cessation in a novel
administration paradigm is consistent with the neurogenic theory
of antidepressant effects, as this time frame corresponds to the
maturation and functional integration of newborn neurons within
ventral hippocampal circuitry following treatment-stimulated
Figure 9. Animals treated with NRG display antidepressant behavior in a forced swim test 28 d after administration. NRG-treated
animals show decreased immobility (A, 44%, p=0.0062; B) and increased swimming behavior (C, 194%, p=0.0062; D), both overall during the
testing phase (A, C) and throughout the task (B, D). Dashed lines denote beginning of testing phase. Bars and points represent means 6 SEM.
*p,0.05, **p,0.01. NRG, neuregulin; SAL, saline.
doi:10.1371/journal.pone.0026610.g009
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modulation of brain plasticity and behavior by peripheral
neurotrophic factors.
Supporting Information
Figure S1 BrdU/ErbB3 colocalization is present for at
least 28 d after cell birth. BrdU-IR cells (red) express ErbB3
(green), 2 h (A), 24 h (Fig. 5), 7 d (B), and 28 d (C) after birth.
Scale bars=20 mm.
(PPT)
Figure S2 Orthogonal views of BrdU/ErbB3 colocaliza-
tion. Orthogonal view of BrdU (red) / ErbB3 (green)
colocalized cells from Fig. 5 and Fig. S1. A,2h ;B,2 4h ;C,7
d; D,2 8d .
(PPT)
Figure S3 Orthogonal views of cell type colocalization.
A, orthogonal view of triple-labeled cell from Fig. 6A. B,
orthogonal view of ErbB3-IR/SOX2-IR/nestin-negative cell from
Fig. 6B. Red, ErbB3; blue, SOX2; green, nestin.
(PPT)
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